- Onyx's drug candidate for multiple myeloma, carfilzomib, uses Captisol technology from Ligand, who stands to receive milestones (next one is acceptance of NDA) and royalties as well as material sales revenue - see more details on LGND research page.
- Complete biotech webcast and catalyst info and links to my notes can be found on the Upcoming Events page.
- Accelerated approval filing was based on phase 2 trial with 257 heavily pretreated MM patients, saw 24% response rate, or ~1/3 if you include those that had at least minor response. 15.6 month overall survival (OS) was very encouraging, as was very low <1% rate of peripheral neuropathy (important issue for proteosome inhibitors)
- full approval will be based on ASPIRE trial - adding carfilzomib to revlimid and dexamethasone for those w/ 1-3 prior treatment failures. We expect enrollment to finish 1h2012
RSS Feed
